Table 2.
Study outcome data for change in management and diagnosis.
| Study | Population (n) | Change in management | Change in diagnosis | Drug changesa | Other change in management |
|---|---|---|---|---|---|
| Bairactaris et al.6 | 61 | NR | 34% | NR | NR |
| Bega et al.7 | 83 | 37% | 43% | 33% | 4% |
| Bhattacharjee et al.10 | 256 | 68% | 46% | 68% | NR |
| Crotty et al.11 | 81 | 65% | 30% | 35% | NR |
| Garcia Vicente et al.12 | 42 | 17% | NR | 17% | NR |
| Graebner et al.13 | 27 | 67% | NR | 52% | NR |
| Hesse et al.14 | 278 | NR | 55% | NR | NR |
| Jennings et al.15 | 35 | NR | NR | NR | NR |
| Kupsch et al.16 | 113 | 49% | 40% | 50%% | 17% |
| Løkkegaard et al.17 | 58 | 43% | NR | NR | NR |
| Marek et al.18 | 701 | NR | 8% | NR | NR |
| Marshall et al.19 | 150 | NR | 49% | 21% | NR |
| Mirpour et al.20 | 134 | 49% | NR | 36% | 13% |
| Oravivattanakul et al.21 | 175 | NR | NR | NR | NR |
| Sadasivan et al.22 | 65 | 63% | 20% | 47% | 6% |
| Siefert et al.23 | 112 | 58% | 28% | NR | NR |
| Sixel-Doring et al.24 | 125 | NR | 6% | NR | NR |
| Thiriez et al.25 | 516 | 60% | 28% | NR | NR |
| Tolosa et al.26 | 118 | 72% | 52% | 36% | 36% |
| Yomtoob et al.27 | 55 | 38% | NR | 38% | NR |
NR not reported.
aDrug changes constituted, start a new drug, change in dose or discontinue a drug.